UnfoldIPThemes

Company patents

Idorsia Pharmaceuticals Ltd

Idorsia Pharmaceuticals Ltd's patent strategy reveals a strong, albeit fluctuating, focus on core pharmaceutical innovation, with Heterocyclic Compounds (64.5% of portfolio) and Pharmaceutical Preparations (58.1%) dominating, despite significant year-over-year volatility like the -73.7% decline in Heterocyclic Compounds in 2024 followed by a +160.0% surge in 2025. While the company maintains a consistent emphasis on Therapeutic Activity (40.3% of portfolio), the complete cessation of patenting in Material & Chemical Analysis and Acyclic / Carbocyclic Compounds since 2025 suggests a strategic shift away from these areas.

Patent Trend by Technology Area

Yearly patent publications since 2023

Product themes

Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.

62 US filings (since 2023) · 6 categories · 7 themes

Targeted Small Molecule Therapeutics

Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.

Heterocyclic Compounds (Pharma)Pharmaceutical PreparationsAcyclic / Carbocyclic Compounds
Who else files here? →
41since 2023
+116.7%YoY
Drug Candidate Synthesis

Methods and intermediates for preparing complex organic molecules intended as active pharmaceutical ingredients (APIs), often involving multi-step synthesis and optimization of reaction pathways.

General Organic Chemistry Methods
Who else files here? →
9since 2023
0.0%YoY
API Solid Form Engineeringfiltered

Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.

Heterocyclic Compounds (Pharma)General Organic Chemistry Methods
Who else files here? →
7since 2023
0.0%YoY
Targeted Drug Formulation Delivery

Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.

Pharmaceutical Preparations
Who else files here? →
6since 2023
0.0%YoY
Immune Checkpoint Modulation

Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.

Therapeutic Activity (Pharma)
Who else files here? →
5since 2023
new
Antibody Engineering & Therapeutics

Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.

Pharmaceutical PreparationsTherapeutic Activity (Pharma)
Who else files here? →
1since 2023
new
Chemical Synthesis of Drug Intermediates

Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.

Heterocyclic Compounds (Pharma)
Who else files here? →
1since 2023
n/a

Patents

Showing 1-10 of 13

API Solid Form Engineering
Page 1 of 2
US 20260098045 A1APPLICATION
C07D498/04

CRYSTALLINE FORM OF (3S,7S,10R,13R)-13-BENZYL-20-FLUORO-7-ISOBUTYL-N-(2-(3-METHOXY-1,2,4-OXADIAZOL-5-YL)ETHYL)-6,9-DIMETHYL-1,5,8,11-TETRAOXO-10-(2,2,2-TRIFLUOROETHYL)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-TETRADECAHYDRO-[1]OXA[4,7,10,14]TETRAAZACYCLOHEPTADECINO[16,17-F]QUINOLINE-3-CARBOXAMIDE

Filed:2023-09-14Pub:2026-04-09
Applicant:Idorsia Pharmaceuticals Ltd

The invention relates to crystalline form of (3S,7S,10R,13R)-13-benzyl-20-fluoro-7-isobutyl-N-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1, 5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide; processes for the preparation thereof, pharmaceutical compositions containing such crystalline form, pharmaceutical compositions prepared from such crystalline form, and their use as a medicament, especially as CFTR modulators.

US 20250340520 A1APPLICATION
C07D239/47

CRYSTALLINE FORMS OF SODIUM (5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)(SULFAMOYL)AMIDE

Filed:2023-05-25Pub:2025-11-06
Applicant:IDORSIA PHARMACEUTICALS LTD

The present invention concerns novel crystalline forms of aprocitentan sodium salt, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as endothelin receptor antagonists.

US 20240116913 A1APPLICATION
C07D413/14

A CRYSTALLINE FORM OF (4-METHYL-2-[1,2,3]TRIAZOL-2-YL-PHENYL)-[(R)-3-(3-[1,2,3]TRIAZOL-2-YL-BENZYL)-MORPHOLIN-4-YL]-METHANONE

Filed:2022-01-28Pub:2024-04-11
Applicant:Idorsia Pharmaceuticals Ltd

The present invention relates to a crystalline form of (4-Methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(R)-3-(3-[1,2,3]triazol-2-yl-benzyl)-morpholin-4-yl]-methanone, a process for the preparation thereof, pharmaceutical compositions comprising the same and its use as an orexin receptor antagonist in the prevention and/or treatment of various orexin receptor-mediated disorders such as Binge-Eating Disorder (BED).

US 11834443 B2GRANTED
C07D413/04

Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol

Filed:2022-07-01Pub:2023-12-05
Applicant:Idorsia Pharmaceuticals Ltd

The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.

US 20230373967 A1APPLICATION
C07D401/14

A STABLE CRYSTALLINE HYDRATE OF CLAZOSENTAN DISODIUM SALT

Filed:2021-11-04Pub:2023-11-23
Applicant:Idorsia Pharmaceuticals Ltd

The present invention relates to a stable hydrate of clazosentan disodium salt, pharmaceutical formulations manufactured using the same and their use as medicaments.

US 11555025 B2GRANTED
C07D401/06

Crystalline form of N-[1-(5-cyano-pyridin-2-ylmethyl)-1 H-pyrazol-3-yl]-2- [4-(1-trifluoromethyl-cyclopropyl)-phenyl-acetamide

Filed:2021-06-11Pub:2023-01-17
Applicant:IDORSIA PHARMACEUTICALS LTD

The present invention relates to crystalline forms of N-[1-(5-cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, pharmaceutical compositions comprising said crystalline forms and their use as T-type calcium channel blockers in the treatment or prevention of diseases or disorders where T-type calcium channels are involved.

US 20230002365 A1APPLICATION
C07D413/04

CRYSTALLINE FORM OF THE COMPOUND (S)-3-{4-[5-(2-CYCLOPENTYL-6-METHOXY-PYRIDIN-4-YL)-[1,2,4]OXADIAZOL-3-YL]-2-ETHYL-6-METHYL-PHENOXY}-PROPANE-1,2-DIOL

Filed:2022-07-01Pub:2023-01-05
Applicant:Idorsia Pharmaceuticals Ltd

The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.

US 20220275011 A1APPLICATION
C07F9/6558

CRYSTALLINE FORMS

Filed:2022-05-10Pub:2022-09-01
Applicant:Idorsia Pharmaceuticals Ltd

The invention relates to crystalline forms of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester hydrochloride, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms and their use as a medicament, especially as a P2Y 12 receptor antagonist.

US 11390615 B2GRANTED
C07D413/04

Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenox

Filed:2020-10-14Pub:2022-07-19
Applicant:IDORSIA PHARMACEUTICALS LTD

The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.

US 11365209 B2GRANTED
C07F9/6558

Crystalline forms

Filed:2020-07-24Pub:2022-06-21
Applicant:IDORSIA PHARMACEUTICALS LTD

The invention relates to crystalline forms of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester hydrochloride, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms and their use as a medicament, especially as a P2Y 12 receptor antagonist.

12